ContraFect Corp (NASDAQ:CFRX) – Analysts at Zacks Investment Research raised their FY2018 EPS estimates for ContraFect in a research note issued on Wednesday. Zacks Investment Research analyst D. Bautz now expects that the biotechnology company will post earnings per share of ($0.34) for the year, up from their prior estimate of ($0.41). Zacks Investment Research also issued estimates for ContraFect’s FY2019 earnings at ($0.36) EPS.
ContraFect (NASDAQ:CFRX) opened at $1.86 on Friday. ContraFect has a 1-year low of $0.80 and a 1-year high of $2.40. The company has a market cap of $145.84, a price-to-earnings ratio of -6.20 and a beta of -0.62.
A number of hedge funds and other institutional investors have recently modified their holdings of CFRX. Deutsche Bank AG raised its holdings in ContraFect by 167.2% in the 4th quarter. Deutsche Bank AG now owns 116,224 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 72,732 shares in the last quarter. Renaissance Technologies LLC raised its holdings in ContraFect by 156.6% in the 4th quarter. Renaissance Technologies LLC now owns 194,500 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 118,700 shares in the last quarter. Anson Funds Management LP purchased a new stake in shares of ContraFect in the 4th quarter worth about $301,000. 683 Capital Management LLC purchased a new stake in shares of ContraFect in the 3rd quarter worth about $2,886,000. Finally, Fosun International Ltd purchased a new stake in shares of ContraFect in the 3rd quarter worth about $9,435,000. Institutional investors and hedge funds own 61.75% of the company’s stock.
ContraFect Company Profile
ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza.
Receive News & Ratings for ContraFect Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ContraFect and related companies with MarketBeat.com's FREE daily email newsletter.